证券代码：600056 证券简称：中国医药 公告编号：临2025-062号 中国医药健康产业股份有限公司 第九届董事会第 30 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 (一)中国医药健康产业股份有限公司(以下简称"公司")第九届董事会第30次 会议（以下简称"本次会议"）于2025年8月8日以现场结合通讯方式召开，会议由董 事长、总经理杨光先生主持，公司监事及相关高级管理人员列席了本次会议。 (二)本次会议通知于2025年8月1日以邮件、短信、电话或传真的方式向全体董 事发出。 (三)本次会议应出席会议董事7名，实际参加会议董事7名。 (四)本次会议的召开符合《公司法》及《公司章程》的有关规定，会议决议为 有效决议。 二、会议审议情况 本次会议审议并通过如下议案： （一）审议通过了《关于修订<公司章程>的议案》。 具体修订情况请详见公司在上海证券交易所网站（www.sse.com.cn）发布的临 2025-063 号公告及公司章程修订稿全文。 表决结果：同意 7 票；反对 0 票；弃权 ...

Group 1 - The core viewpoint emphasizes that building cultural confidence is essential for achieving higher quality development in China's biopharmaceutical industry [1] - China is experiencing rapid development in the biopharmaceutical sector, transitioning from a technology follower to a competitor in various subfields, with some areas showing potential to lead the industry [1] - The transformation is marked by continuous scientific research achievements and steady improvements in clinical translation capabilities, indicating a significant shift in China's position in the global competitive landscape [1] Group 2 - Professor Chen Shuqing from Zhejiang University highlights that as the gap with leading levels narrows, cultural confidence becomes a key support for higher quality development [1] - The historical progress presents unprecedented development opportunities for Chinese youth in the biopharmaceutical field [1]

Group 1 - The core viewpoint of the article highlights the growth in China's pharmaceutical imports and exports in May 2025, indicating a positive trend in the industry [1] Group 2 - In May 2025, China's pharmaceutical imports reached 38,800 tons, representing a year-on-year increase of 4%, with an import value of $4.387 billion, up 1.2% [1] - The export volume of pharmaceutical materials and drugs was 150,000 tons, showing a year-on-year growth of 12.8%, with an export value of $2.422 billion, which is a 16.8% increase compared to the previous year [1]

Group 1: Industry Overview - The Chinese pharmaceutical distribution market can be divided into three competitive tiers, with the first tier consisting of national wholesale giants such as China National Pharmaceutical Group, Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jiuzhoutong, all generating over 100 billion in revenue [1] - The retail pharmacy rankings show Dazhenlin at the top, followed by Guoyao Pharmacy and Yifeng Pharmacy, indicating significant changes in the top five rankings compared to the previous year [3] - The e-commerce segment is led by Ark Health's online pharmacy, which is pioneering a new H2H (Hospital To Home) smart healthcare model [4] Group 2: Strategic Analysis - The strategic cluster analysis of listed companies in the pharmaceutical distribution industry indicates that leaders such as China Resources Pharmaceutical, Shanghai Pharmaceuticals, Jiuzhoutong, and China National Pharmaceutical Group have revenues exceeding 100 billion and are well-established in the market [5] - The competitive landscape is characterized by intense competition, with numerous participants including wholesale and retail pharmaceutical companies, as well as brand operators entering the supply chain [7] Group 3: Competitive Forces - The analysis using Porter's Five Forces model reveals a highly competitive environment in the pharmaceutical distribution industry, with a quantification of competitive forces ranging from 0 (minimum) to 1 (maximum) [7]

Core Insights - The Chinese pharmaceutical distribution market is segmented into three competitive tiers, with major players like China National Pharmaceutical, Shanghai Pharmaceuticals, and China Resources Pharmaceutical leading the first tier with revenues exceeding 100 billion [1] - The retail pharmacy rankings show Dazhenlin at the top, followed by Guoda Pharmacy and Yifeng Pharmacy, indicating significant changes in the rankings from 2022-2023 [3][4] - In the e-commerce sector, Fangzhou Jianke leads the online pharmacy rankings, emphasizing the shift towards technology-driven healthcare solutions [5] Competitive Landscape - The pharmaceutical distribution industry is characterized by intense competition, with numerous participants including wholesale, retail, and brand operation companies, as well as e-commerce platforms entering the market [7] - The five forces analysis indicates a high threat from potential entrants and moderate bargaining power from downstream medical institutions and patients [7] - The strategic cluster analysis reveals that leading companies like China Resources Pharmaceutical and Shanghai Pharmaceuticals are positioned as market leaders due to their extensive experience and comprehensive business layouts [5][6] Retail Pharmacy Rankings - The top five retail pharmacies are Dazhenlin, Guoda Pharmacy, Yifeng Pharmacy, Laobaiyi, and Yixintang, reflecting a dynamic market with significant shifts in rankings [3][4] - Other notable pharmacies in the top 25 include Henan Zhang Zhongjing Pharmacy and Shandong Yanjitang, showcasing a diverse competitive landscape [3] E-commerce Pharmacy Rankings - Fangzhou Jianke leads the online pharmacy sector, followed by 1Yao.com and JD Health, highlighting the growing importance of digital platforms in the pharmaceutical distribution market [5] - The focus on technology and innovation is evident as companies aim to connect patients with medical services more effectively [5]

Core Viewpoint - The collaboration between Shanghai and Taizhou is expected to create new opportunities in the biopharmaceutical industry, enhancing innovation and development in the China Medical City [2] Group 1: Development and Innovation - Taizhou has a unique advantage in the biopharmaceutical sector, being home to the first national high-tech zone for pharmaceuticals and receiving significant policy support from Jiangsu provincial government [2] - The city has established various innovative platforms, including the International Genetic Engineering and Biotechnology Center and the Fudan University Health Science Research Institute, to foster a comprehensive innovation matrix for the biopharmaceutical industry [3] Group 2: Talent Acquisition and Industry Growth - Taizhou focuses on attracting high-level talent and entrepreneurs, having introduced 10 academicians, 75 national high-end experts, and 1,746 high-level talents under various talent programs, ensuring a strong talent foundation for industry development [4] - The city has attracted over 1,300 biopharmaceutical companies, including major players like AstraZeneca and Nestlé, with the health industry expected to exceed 400 billion yuan by 2025 [4] Group 3: Service and Future Prospects - Taizhou is committed to providing specialized, full-chain services to businesses, having established the first comprehensive drug supervision service center in China, which includes four service centers for new drug applications and regulatory reviews [5] - The city aims to leverage the integration of the Yangtze River Delta region to explore future growth areas such as synthetic biology, cell and gene therapy, AI pharmaceuticals, and high-end medical devices, positioning itself as a vibrant hub for biopharmaceutical innovation [5]

Core Insights - The seminar titled "Breakthrough in Mergers and Acquisitions: Investment and Exit Strategies in the Era of Stock" was successfully held in Beijing, focusing on the trends, opportunities, and challenges in the M&A market, particularly in the pharmaceutical industry [1] Group 1: U.S. Pharmaceutical Industry Development - The U.S. pharmaceutical industry has undergone five stages of development: embryonic (1775-1860), birth (1861-1869), formation (1870-1929), growth (1930-1983), and dominance (1984-present) [2] - By 2024, the U.S. pharmaceutical market is projected to reach nearly $800 billion, accounting for over 45% of the global market, with five of the top ten pharmaceutical companies being U.S.-based [2] Group 2: M&A Logic in U.S. Pharmaceutical Industry - M&A activities in the U.S. pharmaceutical sector have evolved: in the 1980s, they focused on horizontal integration; in the 2000s, they addressed patent cliffs and globalization; post-2010, the focus shifted to acquiring innovative technologies [3] - Pfizer and Danaher are highlighted as exemplary companies in M&A, with Pfizer frequently engaging in significant acquisitions to maintain its market dominance, while Danaher excels in integrating acquired assets to enhance profitability [3] Group 3: Trends in Chinese Pharmaceutical Industry M&A - The Chinese pharmaceutical industry is entering an M&A era, with the scale of M&A in the healthcare sector increasing from $11.25 billion in 2018 to $24.514 billion in 2024, rising from seventh to first in industry rankings [4][5] - The current M&A landscape in China is characterized by six types: vertical integration, biotechnology acquisitions, cross-sector diversification, state-owned enterprise reform-driven strategic M&A, cross-border acquisitions, and digital transformation [6] Group 4: Future Outlook for Chinese Pharmaceutical M&A - The number of pharmaceutical companies in China is expected to decrease from 5,000 to 500, indicating a consolidation trend where many companies will exit the market or be acquired [6] - There will be a significant increase in overseas acquisitions by Chinese companies due to intense domestic competition and the need for international expansion [6] - M&A among listed companies is anticipated to occur frequently, enhancing business chain integrity and strengthening core positions in various segments [6]

中国医药健康产业股份有限公司股东大会会议文件 证券代码：600056 证券简称：中国医药 会议资料 中国医药健康产业股份有限公司股东大会会议文件 关于增加 2025 年度预计担保额度的议案 各位股东： 一、增加预计担保额度的基本情况 鉴于金穗科技已正式并入中国医药上市公司体系，为保 障金穗科技业务平稳过渡运转，结合其实际经营需要，拟增 加公司 2025 年度预计担保额度 59,000 万元，担保主体为中 国医药，被担保主体为金穗科技。具体明细如下： 担保方 被担保方 担保类型 担保额度 外部银行担保 39,000 中国医药 金穗科技 业务相关担保 20,000 合计 59,000 注：上述业务相关担保为金穗科技与飞利浦（中国）投资有限公司合作业 务采购付款提供的连带责任保证，中国医药出具不可撤销担保函。 经 5 月 16 日公司 2024 年年度股东大会审议批准，2025 年度公司为控股公司提供担保的额度为 6.92 亿元。本次增 加额度后，公司 2025 年度为控股公司提供担保的预计额度 二、被担保方主要财务数据 金穗科技主要财务数据如下： 指标 单位：万元 | （经审计） | | （未经审计） | | - ...

2025 年第五次临时股东大会 会议资料 中国医药健康产业股份有限公司股东大会会议文件 证券代码：600056 证券简称：中国医药 经 5 月 16 日公司 2024 年年度股东大会审议批准，2025 年度公司为控股公司提供担保的额度为 6.92 亿元。本次增 加额度后，公司 2025 年度为控股公司提供担保的预计额度 总额将由 6.92 亿元增加至 12.82 亿元，为资产负债率 70% 以上的控股公司提供担保的额度由 3.20 亿元增加至 9.10 亿 元。担保事项有效期自股东大会审议通过日至下一年度股东 大会召开之日。 2025 年 8 月 8 日 中国医药健康产业股份有限公司股东大会会议文件 关于增加 2025 年度预计担保额度的议案 各位股东： 一、增加预计担保额度的基本情况 鉴于金穗科技已正式并入中国医药上市公司体系，为保 障金穗科技业务平稳过渡运转，结合其实际经营需要，拟增 加公司 2025 年度预计担保额度 59,000 万元，担保主体为中 国医药，被担保主体为金穗科技。具体明细如下： | 中国医药 | 金穗科技 | | | | --- | --- | --- | --- | | | | 业务 ...

Market Overview - The pharmaceutical commercial sector increased by 1.04% on July 30, with Huaren Health leading the gains [1] - The Shanghai Composite Index closed at 3615.72, up 0.17%, while the Shenzhen Component Index closed at 11203.03, down 0.77% [1] Top Performers - Huaren Health (301408) closed at 15.01, up 5.48% with a trading volume of 334,100 shares and a transaction value of 499 million [1] - Jiazhang Tang (002462) closed at 14.67, up 4.19% with a trading volume of 232,300 shares and a transaction value of 346 million [1] - Laobaixing (603883) closed at 19.69, up 2.93% with a trading volume of 398,800 shares and a transaction value of 779 million [1] - China National Pharmaceutical (600056) closed at 11.28, up 2.64% with a trading volume of 656,900 shares and a transaction value of 747 million [1] Underperformers - Renmin Tongtai (600829) closed at 8.77, down 7.20% with a trading volume of 724,400 shares and a transaction value of 651 million [2] - Saily Medical (603716) closed at 30.89, down 2.31% with a trading volume of 444,300 shares and a transaction value of 1.385 billion [2] - Runda Medical (603108) closed at 18.20, down 1.83% with a trading volume of 299,700 shares and a transaction value of 552 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 62.07 million from institutional investors, while retail investors saw a net inflow of 64.93 million [2] - Major stocks like Laobaixing and China National Pharmaceutical had significant net inflows from retail investors, despite overall sector outflows [3] Individual Stock Analysis - Laobaixing (603883) had a net inflow of 62.57 million from institutional investors, but a net outflow of 45.34 million from retail investors [3] - China National Pharmaceutical (600056) saw a net inflow of 49.86 million from institutional investors, with a net outflow of 43.44 million from retail investors [3] - Huaren Health (301408) had a net inflow of 21.02 million from institutional investors, but a net outflow of 26.49 million from retail investors [3]